Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference in London

ROCKVILLE, Md.--(BUSINESS WIRE)-- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Jefferies 2011 Global Healthcare Conference in London on Tuesday, September 27, 2011 at 3:40 PM BST. During the presentation, a member of the company’s management team will provide a corporate overview, which may include a discussion of the company’s business activities and financial performance.

A webcast of this presentation will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under “Investors.”

About Emergent BioSolutions Inc.

Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders. Additional information about the company may be found at www.emergentbiosolutions.com.



CONTACT:

Emergent BioSolutions Inc.
Investors:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
[email protected]
or
Media:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
[email protected]

KEYWORDS:   United Kingdom  United States  Europe  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Professional Services  Finance

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.